肿瘤放疗与TIM-3分子关系的研究进展
Research Progress on the Relationship between Tumor Radiotherapy and TIM-3
DOI: 10.12677/ACM.2022.1291215, PDF,   
作者: 矫晨晨, 周 非, 周雨媛, 陈文秀, 于洪升*：青岛大学附属医院肿瘤放疗科，山东 青岛；曹万里：青岛市城阳区流亭街道卫生院，山东 青岛
关键词: 放疗；免疫治疗；TIM-3；Radiotherapy； Immunotherapy； T Cell Immunoglobulin Domain and Mucin Domain-3 (TIM-3)
摘要: 放射治疗已被证明具有诱导免疫原性细胞死亡(immunogenetic cell death, ICD)和促进全身免疫应答的作用，因此放射治疗与免疫治疗的结合成为近年来的研究热点。T细胞免疫球蛋白域和粘蛋白域3 (TIM-3)是一种免疫检查点分子，可以影响肿瘤微环境(TME)，在肿瘤进展和调控中发挥重要作用。有证据表明，靶向TIM-3是当前免疫治疗中一种很有前途的治疗方法，特别是与其他免疫检查点阻断剂的新组合。放疗与抗TIM-3或双重免疫治疗是否能取得更好的效果，仍需进一步探讨。本文综述肿瘤放射治疗与TIM-3的关系，为放射治疗与免疫治疗的结合提供新的思路。
Abstract: Radiotherapy has been proved to promote systemic immune response in recent years, so the com-bined application of radiotherapy and immunotherapy has become a research hotspot. T cell im-munoglobulin domain and mucin domain-3 (TIM-3), a kind of immune checkpoint molecule had been proved it can affect the tumor microenvironment and play an important role in tumor pro-gression and regulation. Evidences showed that targeting at TIM-3 is one of the promising immu-notherapies especially the combination of TIM-3 and other immune checkpoint inhibitors. However, whether the combination of radiotherapy and TIM-3 or dual-immunotherapy could achieve better effect still needs further discussion. This article reviews the relationship between tumor radio-therapy and TIM-3, which may provide evidence for the combination of radiotherapy and immuno-therapy.
文章引用：矫晨晨, 周非, 曹万里, 周雨媛, 陈文秀, 于洪升. 肿瘤放疗与TIM-3分子关系的研究进展[J]. 临床医学进展, 2022, 12(9): 8427-8433. https://doi.org/10.12677/ACM.2022.1291215

参考文献

[1] Meyers, J., Sabatos, C., Chakravarti, S., et al. (2005) The TIM Gene Family Regulates Autoimmune and Allergic Dis-eases. Trends in Molecular Medicine, 11, 362-369. [Google Scholar] [CrossRef] [PubMed]
[2] Saleh, R., Toor, S. and Elkord, E. (2020) Targeting TIM-3 in Solid Tumors: Innovations in the Preclinical and Translational Realm and Therapeutic Potential. Expert Opinion on Therapeutic Targets, 24, 1251-1262. [Google Scholar] [CrossRef] [PubMed]
[3] Van de Weyer, P., Muehlfeit, M., Klose, C., et al. (2006) A Highly Conserved Tyrosine of Tim-3 Is Phosphorylated upon Stimulation by Its Ligand Galectin-9. Biochemical and Bi-ophysical Research Communications, 351, 571-576. [Google Scholar] [CrossRef] [PubMed]
[4] Clayton, K., Haaland, M., Douglas-Vail, M., et al. (2014) T Cell Ig and Mucin Domain-Containing Protein 3 Is Recruited to the Immune Synapse, Disrupts Stable Synapse Formation, and Associates with Receptor Phosphatases. Journal of Immunology (Baltimore, MD: 1950), 192, 782-791. [Google Scholar] [CrossRef] [PubMed]
[5] Yu, L., Liu, X., Wang, X., et al. (2021) TIGIT TIM-3 NK Cells Are Correlated with NK Cell Exhaustion and Disease Progression in Patients with Hepatitis B Virus-Related Hepatocel-lular Carcinoma. Oncoimmunology, 10, Article ID: 1942673. [Google Scholar] [CrossRef] 
[6] Kandel, S., Adhikary, P., Li, G., et al. (2021) The TIM3/Gal9 Signaling Pathway: An Emerging Target for Cancer Immunotherapy. Cancer Letters, 510, 67-78. [Google Scholar] [CrossRef] [PubMed]
[7] Tang, D. and Lotze, M. (2012) Tumor Immunity Times Out: TIM-3 and HMGB1. Nature Immunology, 13, 808-810. [Google Scholar] [CrossRef] [PubMed]
[8] Sordi, R., Bet, Â., Della Justina, A., et al. (2020) The Apoptosis Clearance Signal Phosphatidylserine Inhibits Leukocyte Migration and Promotes Inflammation Resolution in Vivo. European Jour-nal of Pharmacology, 877, Article ID: 173095. [Google Scholar] [CrossRef] [PubMed]
[9] Freeman, G., Casasnovas, J., Umetsu, D., et al. (2010) TIM Genes: A Family of Cell Surface Phosphatidylserine Receptors That Reg-ulate Innate and Adaptive Immunity. Immunological Reviews, 235, 172-189. [Google Scholar] [CrossRef] [PubMed]
[10] Zang, K., Hui, L., Wang, M., et al. (2021) TIM-3 as a Prognostic Marker and a Potential Immunotherapy Target in Human Malignant Tumors: A Meta-Analysis and Bioinfor-matics Validation. Frontiers in Oncology, 11, Article 579351. [Google Scholar] [CrossRef] [PubMed]
[11] Gao, X., Zhu, Y., Li, G., et al. (2012) TIM-3 Expression Characterizes Regulatory T Cells in Tumor Tissues and Is Associated with Lung Cancer Progression. PLOS ONE, 7, e30676. [Google Scholar] [CrossRef] [PubMed]
[12] Sun, H., Gao, W., Pan, W., et al. (2017) Tim3+ Foxp3+ Treg Cells Are Potent Inhibitors of Effector T Cells and Are Suppressed in Rheumatoid Arthritis. Inflammation, 40, 1342-1350. [Google Scholar] [CrossRef] [PubMed]
[13] Huang, S., Liu, D., Sun, J., et al. (2022) Tim-3 Regulates Sepsis-Induced Immunosuppression by Inhibiting the NF-κB Signaling Pathway in CD4 T Cells. Molecular Therapy, 30, 1227-1238. [Google Scholar] [CrossRef] [PubMed]
[14] Han, G., Chen, G., Shen, B., et al. (2013) Tim-3: An Activation Marker and Activation Limiter of Innate Immune Cells. Frontiers in Immunology, 4, Article 449. [Google Scholar] [CrossRef] [PubMed]
[15] Li, Y.-H., Zhou, W.-H., Tao, Y., et al. (2016) The Galec-tin-9/Tim-3 Pathway Is Involved in the Regulation of NK Cell Function at the Maternal-Fetal Interface in Early Pregnancy. Cellular & Molecular Immunology, 13, 73-81. [Google Scholar] [CrossRef] [PubMed]
[16] Chew, V., Lee, Y., Pan, L., et al. (2019) Immune Activation Underlies a Sustained Clinical Response to Yttrium-90 Radioembolisation in Hepatocellular Carcinoma. Gut, 68, 335-346. [Google Scholar] [CrossRef] [PubMed]
[17] Galluzzi, L., Buqu, A., Kepp, O., et al. (2017) Immunogenic Cell Death in Cancer and Infectious Disease. Nature Reviews Immunology, 17, 97-111. [Google Scholar] [CrossRef] [PubMed]
[18] Chen, Q., Sun, L. and Chen, Z. (2016) Regulation and Function of the cGAS-STING Pathway of Cytosolic DNA Sensing. Nature Immunology, 17, 1142-1149. [Google Scholar] [CrossRef] [PubMed]
[19] Sun, L., Wu, J., Du, F., et al. (2013) Cyclic GMP-AMP Synthase Is a Cyto-solic DNA Sensor That Activates the Type I Interferon pathway. Science (New York, NY), 339, 786-791. [Google Scholar] [CrossRef] [PubMed]
[20] Rodriguez-Ruiz, M., Rodriguez, I., Leaman, O., et al. (2019) Immune Mechanisms Mediating Abscopal Effects in Radioimmunotherapy. Pharmacology & Therapeutics, 196, 195-203. [Google Scholar] [CrossRef] [PubMed]
[21] Sato, H., Niimi, A., Yasuhara, T., et al. (2017) DNA Dou-ble-Strand Break Repair Pathway Regulates PD-L1 Expression in Cancer Cells. Nature Communications, 8, Article No. 1751. [Google Scholar] [CrossRef] [PubMed]
[22] Azad, A., Lim, S.Y., D’costa, Z., et al. (2017) PD-L1 Blockade Enhances Response of Pancreatic Ductal Adenocarcinoma to Radiotherapy. EMBO Molecular Medicine, 9, 167-180. [Google Scholar] [CrossRef] [PubMed]
[23] Tu, X., Qin, B., Zhang, Y., et al. (2019) PD-L1 (B7-H1) Competes with the RNA Exosome to Regulate the DNA Damage Response and Can Be Targeted to Sensitize to Radia-tion or Chemotherapy. Molecular Cell, 74, 1215-1226.e4. [Google Scholar] [CrossRef] [PubMed]
[24] Formenti, S., Rudqvist, N., Golden, E., et al. (2018) Radiothera-py Induces Responses of Lung Cancer to CTLA-4 Blockade. Nature Medicine, 24, 1845-1851. [Google Scholar] [CrossRef] [PubMed]
[25] Theelen, W., Peulen, H., Lalezari, F., et al. (2019) Effect of Pem-brolizumab after Stereotactic Body Radiotherapy vs Pembrolizumab Alone on Tumor Response in Patients with Ad-vanced Non-Small Cell Lung Cancer: Results of the PEMBRO-RT Phase 2 Randomized Clinical Trial. JAMA Oncology, 5, 1276-1282. [Google Scholar] [CrossRef] [PubMed]
[26] Shaverdian, N., Lisberg, A., Bornazyan, K., et al. (2017) Previ-ous Radiotherapy and the Clinical Activity and Toxicity of Pembrolizumab in the Treatment of Non-Small-Cell Lung Cancer: A Secondary Analysis of the KEYNOTE-001 Phase 1 Trial. The Lancet Oncology, 18, 895-903. [Google Scholar] [CrossRef] 
[27] Yamaguchi, O., Kaira, K., Hashimoto, K., et al. (2019) Radi-otherapy Is an Independent Prognostic Marker of Favorable Prognosis in Non-Small Cell Lung Cancer Patients after Treatment with the Immune Checkpoint Inhibitor, Nivolumab. Thoracic Cancer, 10, 992-1000. [Google Scholar] [CrossRef] [PubMed]
[28] 赵春燕, 唐嘉迎. 外周血Tim-3表达水平与食管癌放化疗敏感性的相关性研究[J]. 河北医学, 2021, 27(6): 886-892.
[29] Sonanini, D., Griessinger, C., Schörg, B., et al. (2021) Low-Dose Total Body Irradiation Facilitates Antitumoral Th1 Immune Responses. Theranostics, 11, 7700-7714. [Google Scholar] [CrossRef] [PubMed]
[30] Verbrugge, I., Hagekyriakou, J., Sharp, L., et al. (2012) Radiotherapy In-creases the Permissiveness of Established Mammary Tumors to Rejection by Immunomodulatory Antibodies. Cancer Research, 72, 3163-3174. [Google Scholar] [CrossRef] 
[31] Ruan, Y., Hu, W., Li, W., et al. (2019) Analysis of Plasma EBV-DNA and Soluble Checkpoint Proteins in Nasopharyngeal Carcinoma Patients after Definitive Intensity-Modulated Radiotherapy. BioMed Research International, 2019, Article ID: 3939720. [Google Scholar] [CrossRef] [PubMed]
[32] Peng, Q., Li, J., Xin, P., et al. (2021) Assessment of the Expression and Response of PD-1, LAG-3, and TIM-3 after Neoadjuvant Radiotherapy in Rectal Cancer. Neoplasma, 68, 742-750. [Google Scholar] [CrossRef] 
[33] Filatenkov, A., Baker, J., Mueller, A., et al. (2015) Ablative Tumor Radiation Can Change the Tumor Immune Cell Microenvironment to Induce Durable Complete Remissions. Clin-ical Cancer Research, 21, 3727-3739. [Google Scholar] [CrossRef] 
[34] Dong, D.-N., Fan, P.-W., Feng, Y.-N., Liu, G.-H., et al. (2021) Association between Circulating CD39+CD8+ T Cells Pre-Chemoradiotherapy and Prognosis in Patients with Nasopharyngeal Carcinoma. Chinese Medical Journal, 134, 2066-2072. [Google Scholar] [CrossRef] 
[35] Liu, M., Li, Z., Yao, W., et al. (2020) IDO Inhibitor Syner-gized with Radiotherapy to Delay Tumor Growth by Reversing T Cell Exhaustion. Molecular Medicine Reports, 21, 445-453. [Google Scholar] [CrossRef] [PubMed]
[36] Petersen, S., Kua, L., Nakajima, S., Yong, W., et al. (2021) Chemoradiation Induces Upregulation of Immunogenic Cell Death-Related Molecules Together with Increased Expres-sion of PD-L1 and Galectin-9 in Gastric Cancer. Scientific Reports, 11, Article No. 12264. [Google Scholar] [CrossRef] [PubMed]
[37] Shayan, G., Srivastava, R., Li, J., et al. (2017) Adaptive Re-sistance to Anti-PD1 Therapy by Tim-3 Upregulation Is Mediated by the PI3K-Akt Pathway in Head and Neck Cancer. Oncoimmunology, 6, e1261779. [Google Scholar] [CrossRef] 
[38] Ngiow, S., Von Scheidt, B., Akiba, H., et al. (2011) An-ti-TIM3 Antibody Promotes T Cell IFN-γ-Mediated Antitumor Immunity and Suppresses Established Tumors. Cancer Research, 71, 3540-3551. [Google Scholar] [CrossRef] 
[39] Oweida, A., Hararah, M., Phan, A., et al. (2018) Resistance to Radiotherapy and PD-L1 Blockade Is Mediated by TIM-3 Upregulation and Regulatory T-Cell Infiltration. Clinical Cancer Research, 24, 5368-5380. [Google Scholar] [CrossRef] 
[40] Anderson, A.C., Joller, N. and Kuchroo, V.K. (2016) Lag-3, Tim-3, and TIGIT: Co-Inhibitory Receptors with Specialized Functions in Immune Regulation. Immunity, 44, 989-1004. [Google Scholar] [CrossRef] [PubMed]

为你推荐